PATENT CLAIM ANALYSIS

Application Number: 16210765
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-09
Patent Classification: ["514", "365000"]

Abstract:
A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.

Claim (Index 3):
The method of  claim 1 , wherein the step of administering ITE or one of its structural analogs is selected from a group consisting of topical, enteral, and parenteral application.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.80247
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15613808', '16047805', '14961325', '13952030', '13503657']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8903897971717097
- 35 USC 102 Novelty (BERT): 0.6409336835942888
- Combined Prediction Score: 0.8654441858139676
- Mean Citation Score: 619.584646
- Max Citation Score: 649.8505
- Similarity Product: 569.0472768639328

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test